Log in
Enquire now
Xencor

Xencor

A biopharmaceutical company, focused on the discovery and development of monoclonal antibody therapeutics to treat autoimmune, allergic diseases and cancer

OverviewStructured DataIssuesContributors

Contents

xencor.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Healthcare
Healthcare
Technology
Technology
Engineering
Engineering
0
Proteomics
Proteomics
Immunotherapy
Immunotherapy
Autoimmune disease
Autoimmune disease
Biomedical engineering
Biomedical engineering
...
Location
Monrovia
Monrovia
Monrovia, California
Monrovia, California
0
San Diego
San Diego
0
B2X
B2B
B2B
CEO
‌
Bassil I. Dahiyat
0
Founder
‌
Bassil I. Dahiyat
0
AngelList URL
angel.co/xencor
Legal Name
Xencor, Inc.0
Legal classification
Public company
Public company
0
Number of Employees (Ranges)
201 – 500
Email Address
collaborate@xencor.com0
info@xencor.com0
Phone Number
+185861761550
+162630559000
Number of Employees
2540
Full Address
12481 High Bluff Dr., Suite 200 San Diego, CA 921300
111 W. Lemon Avenue Monrovia, CA 910160
CIK Number
1,326,732
Place of Incorporation
Delaware
Delaware
Investors
Novo Nordisk
Novo Nordisk
‌
Merlin Nexus
DUNS Number
0235809420
IRS Number
201,622,502
Founded Date
1997
0
Total Funding Amount (USD)
50,147,760
Latest Funding Round Date
November 19, 2021
Stock Symbol
XNCR
Exchange
Nasdaq
Nasdaq
0
Board of Directors
‌
A. Bruce Montgomery
0
‌
Nancy Valente
0
‌
Ellen G. Feigal
0
‌
Richard Ranieri
0
‌
Kurt Gustafson
0
Kevin C. Gorman
Kevin C. Gorman
0
‌
Bassil I. Dahiyat
0
‌
Dagmar Rosa-Bjorkeson
0
CFO
‌
John J. Kuch
0
NAICS Code
325,4120
CAGE Code
1NUG90
Patents Assigned (Count)
144
Wellfound ID
xencor
Country
United States
United States
Headquarters
Monrovia, California
Monrovia, California
0

Other attributes

Company Operating Status
Active
Contact Page URL
xencor.com/contact-us/
SIC Code
2,834
Ticker Symbol
XNCR0
Wikidata ID
Q106411729

Xencor is expanding the therapeutic boundaries of antibody and cytokine drugs. Powered by its XmAb® protein engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat patients with cancer and autoimmune disorders. More than 20 programs are in clinical testing, and many more are in preclinical development. Three XmAb medicines are marketed by partners. More About Xencor.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Xencor | Xencor

https://xencor.com/

Web

February 23, 2016

References

Find more companies like Xencor

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.